We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Fluorine-18-α–Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00464282
First Posted: April 23, 2007
Last Update Posted: April 23, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Gunma University
  Purpose

Objective: L-[3-18F]-α–methyltyrosine (FMT) is an amino-acid tracer for PET. We evaluated the diagnostic usefulness of 18F-FMT PET in non-small cell lung cancer (NSCLC) patients. Tumor uptake of 18F-FMT PET was compared with 18F-FDG PET and the correlation with L-type amino acid transporter 1 (LAT1) expression also investigated.

Method: Fifty patients with NSCLC were enrolled in this study, and a pair of PET study with 18F-FMT and 18F-FDG was performed. LAT1 expression and Ki-67 labeling index of the resected tumors were analyzed by immunohistochemical study.


Condition
Carcinoma, Non-Small-Cell Lung

Study Type: Observational
Study Design: Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Gunma University:

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   8 Months to 2 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • proven or suspected non-small cell lung cancer

Exclusion Criteria:

  • uncontrolled diabetes mellitus
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00464282


Sponsors and Collaborators
Gunma University
Investigators
Principal Investigator: kyoichi kaira, MD Gunma Unversity Graduate School of Medicine
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00464282     History of Changes
Other Study ID Numbers: Gunma 444
First Submitted: April 20, 2007
First Posted: April 23, 2007
Last Update Posted: April 23, 2007
Last Verified: April 2007

Keywords provided by Gunma University:
Fluorine–18-α–methyltyrosine,
Positron emission tomography,
Fluorodeoxyglucose
Lung cancer,
Amino acid transportor 1,
Ki-67
Proven or suspected non-small cell lung cancer were enrolled in the study

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
alpha-Methyltyrosine
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action